EHA 2024 | A Phase II trial of intermittent treatment strategies for NDMM to avoid ASCT
Maher Salamoon, MD, Al-Baironi Hospital, Damascus, Syria, presents findings from a Phase II trial exploring intermittent treatment strategies for newly diagnosed multiple myeloma (NDMM) to avoid autologous stem cell transplantation (ASCT). This study, involving approximately 123 patients across three arms—bortezomib plus thalidomide plus dexamethasone, lenalidomide plus dexamethasone, and bortezomib plus dexamethasone—evaluated responses every three months. With a 91% five-year survival rate, this less toxic treatment option proves feasible and effective for many patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
